Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia
source: PLOS ONE
authors: Schaefer BA, Flanagan JM, Alvarez OA, Nelson SC, Aygun B, Nottage KA, George A, Roberts CW, Piccone CM, Howard TA, Davis BR, Ware REsummary/abstract:
Discovery and validation of genetic variants that influence disease severity in children with sickle cell anemia (SCA) could lead to early identification of high-risk patients, better screening strategies, and intervention with targeted and preventive therapy. We hypothesized that newly identified genetic risk factors for the general African American population could also impact laboratory biomarkers known to contribute to the clinical disease expression of SCA, including variants influencing the white blood cell count and the development of albuminuria and abnormal glomerular filtration rate. We first investigated candidate genetic polymorphisms in well-characterized SCA pediatric cohorts from three prospective NHLBI-supported clinical trials: HUSTLE, SWiTCH, and TWiTCH. We also performed whole exome sequencing to identify novel genetic variants, using both a discovery and a validation cohort. Among candidate genes, DARC rs2814778 polymorphism regulating Duffy antigen expression had a clear influence with significantly increased WBC and neutrophil counts, but did not affect the maximum tolerated dose of hydroxyurea therapy. The APOL1 G1 polymorphism, an identified risk factor for non-diabetic renal disease, was associated with albuminuria. Whole exome sequencing discovered several novel variants that maintained significance in the validation cohorts, including ZFHX4 polymorphisms affecting both the leukocyte and neutrophil counts, as well as AGGF1, CYP4B1, CUBN, TOR2A, PKD1L2, and CD163 variants affecting the glomerular filtration rate. The identification of robust, reliable, and reproducible genetic markers for disease severity in SCA remains elusive, but new genetic variants provide avenues for further validation and investigation.organization: Cincinnati Children's Hospital Medical Center; Baylor College of Medicine,USA; University of Miami; Children's Hospitals and Clinics of Minnesota,USA; Cohen Children's Medical Center, USA; St. Jude Children's Research Hospital, Memphis; University of South Carolina; Case Western Reserve University, Cleveland, OH; University of Texas School of Public Health
read more full text
Blood Disorders That the Newborn Screen DetectsToday in the United States all newborns ...
Coaches: Don’t Let Your Athletes Get Sidelined by Sickle Cell Trait!Participating in regular physical activi...
How This Disease Changes the Shape of Your Cells – Amber M. Yateshttps://www.youtube.com/watch?v=hRnrIpUM...
About Pediatric Sickle Cell Diseasehttps://www.onescdvoice.com/wp-content/u...
Experimental Gene Therapy Reverses Sickle Cell Disease for YearsA study of an investigational gene thera...
Novel Sickle Cell Drug Causes Radical Results in End of Life PatientsThis week the FDA approved a novel treat...
New digital education platform for the SCD communityhttps://www.onescdvoice.com/wp-content/u...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.